Muhammad Younis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Muhammad Younis has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Abigail Moore
Department of Pediatrics, Hematology/Oncology, College of Medicine, Pennsylvania State University, Hershey, PA 17033, USA
1 shared publication - Chandrika Gowda
Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
1 shared publication - Divya Gandra
Department of Pediatrics, Hematology/Oncology, College of Medicine, Pennsylvania State University, Hershey, PA 17033, USA
1 shared publication - Franklin Back
Department of Pediatrics, Hematology/Oncology, College of Medicine, Pennsylvania State University, Hershey, PA 17033, USA
1 shared publication - Giselle Saulnier Sholler
Penn State University, College of Medicine, Hershey, PA
1 shared publication - Hong-Gang Wang
The Pennsylvania State University College of Medicine
1 shared publication
Latest Publications
- Open Access
Establishment of Patient-Derived Organoids for Pediatric Cancer Research
Background/Objectives: Pediatric cancers are disorders of dysregulated development driven largely by genomic and epigenetic alterations. Precisely modeling these developmental differences is essential for understanding the unique biology of childhood cancers. Patient-derived organoids (PDOs) offer a powerful in vitro platform that recapitulates tumor heterogeneity, plasticity, microenvironment (including immune cells) and disease-relevant features. Methods: Here, we describe a step-by-step protocol for the establishment of PDOs from cells derived from pediatric brain tumors and extracranial solid tumor biopsies and bone marrow aspirates, including tumor processing, organoid culture/subculture, and cryopreservation. Results: Furthermore, we present the use of PDOs for further experimental analysis such as fluorescence imaging, Western blotting, flow cytometry, and immunohistochemistry (IHC) to investigate the underlying pathophysiology of tumorigenesis. Conclusions: Expanding the application of organoids to childhood malignancies holds exceptional promise for elucidating pediatric tumor biology and advancing therapeutic strategies, representing the long-overdue convergence of technology and clinical need.
Open AccessEstablishment of Patient-Derived Organoids for Pediatric Cancer Research
Background/Objectives: Pediatric cancers are disorders of dysregulated development driven largely by genomic and epigenetic alterations. Precisely modeling these developmental differences is essential for understanding the unique biology of childhood cancers. Patient-derived organoids (PDOs) offer a powerful in vitro platform that recapitulates tumor heterogeneity, plasticity, microenvironment (including immune cells) and disease-relevant features. Methods: Here, we describe a step-by-step protocol for the establishment of PDOs from cells derived from pediatric brain tumors and extracranial solid tumor biopsies and bone marrow aspirates, including tumor processing, organoid culture/subculture, and cryopreservation. Results: Furthermore, we present the use of PDOs for further experimental analysis such as fluorescence imaging, Western blotting, flow cytometry, and immunohistochemistry (IHC) to investigate the underlying pathophysiology of tumorigenesis. Conclusions: Expanding the application of organoids to childhood malignancies holds exceptional promise for elucidating pediatric tumor biology and advancing therapeutic strategies, representing the long-overdue convergence of technology and clinical need.